Adults with newly diagnosed AML, aged ≥ 75 years or with comorbidities that preclude use of intensive induction chemotherapy; susceptible IDH‐1 mutation‐positive; in combination with azacitidine or as monotherapy. The gene discussed is IDH1; the disease is acute myeloid leukemia.